News
ARQT
12.69
+3.59%
0.44
Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
TipRanks · 3d ago
Weekly Report: what happened at ARQT last week (1202-1206)?
Weekly Report · 4d ago
ARCUTIS ANNOUNCES PROMOTIONS ON EXECUTIVE MANAGEMENT TEAM
Reuters · 12/03 13:00
Press Release: Arcutis Announces Promotions on Executive Management Team
Dow Jones · 12/03 13:00
Mizuho Securities Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT)
TipRanks · 12/03 06:46
Weekly Report: what happened at ARQT last week (1125-1129)?
Weekly Report · 12/02 09:15
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump
Simply Wall St · 11/27 10:24
Weekly Report: what happened at ARQT last week (1118-1122)?
Weekly Report · 11/25 09:14
Arcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term Fluctuations
TipRanks · 11/25 07:36
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
NASDAQ · 11/19 14:55
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
NASDAQ · 11/19 14:35
Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
TipRanks · 11/19 07:15
Arcutis Biotherapeutics: What Lies Ahead
Seeking Alpha · 11/18 15:29
Weekly Report: what happened at ARQT last week (1111-1115)?
Weekly Report · 11/18 09:14
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Seeking Alpha · 11/15 13:30
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
NASDAQ · 11/11 14:55
TD Cowen Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)
TipRanks · 11/11 12:47
Weekly Report: what happened at ARQT last week (1104-1108)?
Weekly Report · 11/11 09:15
Arcutis Biotherapeutics: Strong Financial Outlook and Strategic Growth Justify Buy Rating and $19 Price Target
TipRanks · 11/08 15:16
ARCUTIS BIOTHERAPEUTICS INC <ARQT.O>: GUGGENHEIM RAISES TARGET PRICE TO $29 FROM $27
Reuters · 11/08 12:28
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.